TY  - JOUR
DA  - 2021/03/01
VL  - 7
SP  - e09
AU  - Diarra, Ava
AU  - Gantois, Guillaume
AU  - Lazrek, Mouna
AU  - Verdier, Basile
AU  - Elsermans, Vincent
AU  - Zephir, Helene
AU  - Longere, Benjamin
AU  - Gkizas, Xristos
AU  - Goeminne, Celine
AU  - Lemesle, Gilles
AU  - Juthier, Francis
AU  - Bene, Johana
AU  - Launay, David
AU  - Dubois, Romain
AU  - Morell-Dubois, Sandrine
AU  - Vuotto, Fanny
AU  - Piton, Anne-Laure
TI  - Fatal enterovirus-related myocarditis in a patient with devic's syndrome treated with rituximab
DO  - 10.15420/cfr.2020.33
JA  - Card Fail Rev
LA  - Anglais
UR  - http://hdl.handle.net/20.500.12210/40450
SN  - 2057-7540
AB  - Enteroviruses are a frequent source of infection and among the most common central nervous system viral pathogens. Enteroviruses - in particular, the Coxsackie B viruses - are a known cause of myocarditis. Rituximab is a genetically engineered chimeric anti-CD20 monoclonal antibody. Many reports in the literature suggest a higher risk of infection following repeated rituximab therapy, including viral infection. However, observations of enterovirus-related myocarditis in the context of rituximab treatment are scarce. The authors describe the case of a patient with neuromyelitis optica spectrum disorder who developed severe and fatal enterovirus-related myocarditis after rituximab therapy with a difficult differential diagnosis of autoimmune or giant-cell myocarditis. This case highlights the importance of complete diagnostic workup in difficult cases of myocarditis, including endomyocardial biopsies.
JO  - Card Fail Rev
ER  - 
